Response rate as an endpoint for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer
Open Access
- 1 October 1998
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 9 (10) , 1079-1084
- https://doi.org/10.1023/a:1008473003445
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.Journal of Clinical Oncology, 1994
- Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.Journal of Clinical Oncology, 1994
- A phase II study of high dose epirubicin in unresectable non small cell lung cancerBritish Journal of Cancer, 1992
- A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.Journal of Clinical Oncology, 1992
- A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non-Small-Cell Lung CancerAmerican Journal of Clinical Oncology, 1991
- Phase II study of 5-day continuous infusion ofcis-diamminedichloroplatinum(II) in the treatment of non-small-cell lung cancerCancer Chemotherapy and Pharmacology, 1990
- Cisplatin Dose Intensity in Non-Small Cell Lung Cancer: Phase II Results of a Day 1 and Day 8 High-Dose RegimenJNCI Journal of the National Cancer Institute, 1989
- Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.Journal of Clinical Oncology, 1988
- Ifosfamide in the treatment of recurrent or disseminated lung cancerA phase II study of two dose schedulesCancer, 1978